FrancophonIA/ELRC3.0 huggingface dataset:
English: Driving and using machines If you feel dizzy while taking Zomarist, do not drive or use any tools or machines.
Croatian: Ako osjećate omaglicu dok uzimate Zomarist, nemojte upravljati vozilima niti raditi s alatima ili strojevima.
English: Confirmed heart failure (HF) events defined as HF requiring hospitalisation or new onset of HF were reported in 41 (0.43%) vildagliptin-treated patients and 32 (0.45%) comparator-treated patients with M-H RR 1.08 (95% CI 0.68-1.70).
Croatian: Potvrđeni događaji zatajenja srca, definirani kao zatajenje srca koje zahtijeva hospitalizaciju ili nova pojava zatajenja srca, bili su prijavljeni u 41 (0,43%) bolesnika liječenog vildagliptinom i 32 (0,45%) bolesnika liječena komaparatorom s M-H RR 1,08 (95% interval pouzdanosti 0,68-1,70).
English: In these cases, the patients were generally asymptomatic without clinical sequelae and liver function returned to normal after discontinuation of treatment.
Croatian: U tim slučajevima bolesnici su općenito bili bez simptoma i kliničkih posljedica, a jetrena funkcija se vratila na normalu nakon prekida liječenja.
English: Vildagliptin/metformin 50 mg/1000 mg twice daily reduced HbA1c by -1.82%, vildagliptin/metformin 50 mg/500 mg twice daily by -1.61%, metformin 1000 mg twice daily by -1.36% and vildagliptin 50 mg twice daily by -1.09% from a mean baseline HbA1c of 8.6%.
Croatian: Kombinacija vildagliptin/metformin u dozi od 50 mg/1000 mg dva puta na dan snizila je HbA1c za -1,82%, kombinacija vildagliptin/metformin u dozi od 50 mg/500 mg dva puta na dan za -1,61%, metformin 1000 mg dva puta na dan za -1,36%, a vildagliptin 50 mg dva puta na dan za -1,09% od početne srednje vrijednosti HbA1c od 8,6%.
English: Table 5 Adverse reactions for metformin component
Croatian: Tablica 5 Nuspojave metformina
English: See section 4
Croatian: Pogledajte dio 4.
English: Combinations requiring precautions for use
Croatian: Kombinacije koje treba primjenjivati s oprezom
English: Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see also sections 4.3 and 4.5).
Croatian: Drugi čimbenici rizika za laktacidozu su prekomjerni unos alkohola, insuficijencija jetre, neodgovarajuće kontrolirana šećerna bolest, ketoza, dugotrajno gladovanje i svako stanje povezano s hipoksijom, kao i istodobna primjena lijekova koji mogu uzrokovati laktacidozu (vidjeti dijelove 4.3 i 4.5).
English: Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were noted at doses ≥ 20 mg/kg/day (approximately 3 times human AUC exposure at the 100 mg dose).
Croatian: Ljuskanje kože, ljuštenje kože, kraste i rane na repu s histopatološkim promjenama koje su bile s time povezane, zabilježene su kod doza ≥20 mg/kg/dan (približno 3-struka AUC izloženost u ljudi pri dozi od 100 mg).
English: Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent, and accordingly the metabolic clearance of vildagliptin is not anticipated to be affected by comedications that are CYP 450 inhibitors and/or inducers.
Croatian: Vildagliptin se ne metabolizira enzimima CYP 450 do bilo kojeg mjerljivog opsega i zbog toga se ne očekuje da na metabolički klirens vildagliptina utječe istodobna primjena lijekova koji su inhibitori i/ili induktori CYP 450.
English: The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 and GIP.
Croatian: Primjena vildagliptina rezultira brzom i potpunom inhibicijom aktivnosti DPP-4 koja dovodi do povišene endogene razine inkretinskih hormona GLP-1 i GIP natašte i postprandijalno.
English: Liver function should be monitored during treatment with Zomarist at three-month intervals during the first year and periodically thereafter.
Croatian: Jetrenu funkciju treba pratiti tijekom liječenja Zomaristom u razmacima od tri mjeseca tijekom prve godine liječenja te povremeno nakon toga.
English: Therefore, you should not receive Zomarist for the treatment of type 1 diabetes.
Croatian: Stoga ne smijete uzimati Zomarist za liječenje šećerne bolesti tipa
English: Gastrointestinal symptoms, particularly soft faeces, mucoid faeces, diarrhoea and, at higher doses, faecal blood were observed in dogs.
Croatian: Gastrointestinalni simptomi, osobito mekana stolica, sluzava stolica, proljev i pri višim dozama, krv u stolici zapaženi su u pasa.
English: The noeffect dose in rats was 25 mg/kg (5-fold human exposure based on AUC) and in mice 750 mg/kg (142fold human exposure).
Croatian: U štakora je doza bez učinka bila 25 mg/kg (5-struka izloženost u ljudi na temelju AUC-a), a u miševa 750 mg/kg (142-struka izloženost u ljudi).
English: Symptoms of lactic acidosis include: - vomiting - stomach ache (abdominal pain) - muscle cramps - a general feeling of not being well with severe tiredness - difficulty in breathing - reduced body temperature and heartbeat
Croatian: Simptomi laktacidoze uključuju: - povraćanje - bol u trbuhu (bol u abdomenu) - grčevi u mišićima - opće loše osjećanje uz jaki umor - otežano disanje - smanjena tjelesna temperatura i usporen rad srca
English: When Zomarist is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.
Croatian: Kad se Zomarist primjenjuje u kombinaciji sa sulfonilurejom, može se razmotriti niža doza sulfonilureje kako bi se smanjio rizik od hipoglikemije.
English: How to take Zomarist
Croatian: Kako uzimati Zomarist
English: The data presented here relate to the co-administration of vildagliptin and metformin, where vildagliptin has been added to metformin.
Croatian: Ovdje prikazani podaci odnose se na istodobnu primjenu vildagliptina i metformina kada je vildagliptin dodan metforminu.
English: A mean weight gain of +1.9 kg was observed in patients receiving pioglitazone added to metformin compared to +0.3 kg in those receiving vildagliptin added to metformin.
Croatian: Srednja vrijednost dobitka na težini od +1,9 kg bila je zapažena u bolesnika koji su primali pioglitazon kao dodatak metforminu u usporedbi s +0,3 kg u onih bolesnika koji su primali vildagliptin kao dodatak metforminu.
English: Should an increase in AST or in ALT of 3x ULN or greater persist, withdrawal of Zomarist therapy is recommended.
Croatian: Potraju li povišene vrijednosti AST-a ili ALT-a na razini od 3x GGN ili većoj, preporučuje se prekinuti terapiju Zomaristom.
English: Metformin partitions into erythrocytes.
Croatian: Metformin se raspodjeljuje u eritrocite.
English: • Very common (may affect more than 1 in 10 people): nausea, vomiting, diarrhoea, pain in and around the stomach (abdominal pain), loss of appetite.
Croatian: • vrlo često (mogu se javiti u više od 1 na 10 osoba): mučnina, povraćanje, proljev, bol u i oko želuca (bol u trbuhu), gubitak apetita.
English: Vildagliptin in combination with insulin significantly decreased HbA1c compared with placebo.
Croatian: Vildagliptin u kombinaciji s inzulinom značajno je snizio HbA1c u usporedbi s placebom.
English: Analysis of the results for overweight patients treated with metformin after failure of diet alone showed: - a significant reduction in the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patientyears), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034; - a significant reduction in the absolute risk of diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017; - a significant reduction in the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patientyears (p=0.021); - a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years (p=0.01).
Croatian: Prospektivno randomizirano ispitivanje UKPDS (UK Prospective Diabetes Study) potvrdilo je dugotrajnu korist intenzivne kontrole glukoze u krvi u šećernoj bolesti tipa 2. Analiza rezultata u bolesnika s prekomjernom tjelesnom težinom liječenih metforminom nakon neuspjeha same dijete je pokazala: - značajno smanjenje apsolutnog rizika za bilo koju dijabetičku komplikaciju u skupini liječenoj metforminom (29,8 događaja/1000 bolesnik-godina) u usporedbi sa skupinom koja je liječena samo dijetom (43,3 događaja/1000 bolesnik-godina), p=0,0023, te u usporedbi sa skupinama liječenim kombinacijom uz sulfonilureju i monoterapijom inzulinom (40,1 događaja/1000 bolesnik-godina), p=0,0034; - značajno smanjenje apsolutnog rizika mortaliteta vezanog uz šećernu bolest: metformin 7,5 događaja/1000 bolesnik-godina, samo dijeta 12,7 događaja/1000 bolesnik-godina, p=0,017; - značajno smanjenje apsolutnog rizika ukupnog mortaliteta: metformin 13,5 događaja/1000 bolesnik-godina u usporedbi sa skupinom koja je liječena samo dijetom 20,6 događaja/1000 bolesnik-godina (p=0,011) te u usporedbi sa skupinama liječenim kombinacijom uz sulfonilureju i monoterapijom inzulinom (18,9 događaja/1000 bolesnikgodina (p=0,021); - značajno smanjenje apsolutnog rizika za infarkt miokarda: metformin 11 događaja/1000 bolesnik-godina, samo dijeta 18 događaja/1000 bolesnik-godina (p=0,01).
English: Vildagliptin acts primarily by inhibiting DPP-4, the enzyme responsible for the degradation of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
Croatian: Vildagliptin primarno djeluje inhibirajući DPP-4, enzim koji je odgovoran za razgradnju inkretinskih hormona GLP-1 (glukagonu sličan peptid 1) i GIP (inzulinotropni polipeptid ovisan o glukozi).
English: Adverse reactions reported in patients who received vildagliptin in double-blind studies as monotherapy and add-on therapies are listed below by system organ class and absolute frequency.
Croatian: Nuspojave zabilježene u bolesnika koji su primali vildagliptin u dvostruko slijepim ispitivanjima kao monoterapiju i kao dodatnu terapiju navedene su niže za svaku indikaciju prema klasifikaciji organskih sustava i apsolutnoj učestalosti.
English: The following data are findings from studies performed with vildagliptin or metformin individually.
Croatian: Sljedeći podaci odnose se na nalaze ispitivanja provedenih posebno s vildagliptinom i metforminom.
English: Cationic active substances
Croatian: Kationske djelatne tvari
English: The incidence of hypoglycaemia was similar in both treatment groups (14.0% in the vildagliptin group vs 16.4% in the placebo group).
Croatian: Incidencija hipoglikemije bila je slična u obje skupine ispitanika (14,0% u skupini na vildagliptinu u odnosu na 16,4% u skupini na placebu).
English: The incidence of hypoglycaemia was significantly lower in the vildagliptin group (1.7%) than in the glimepiride group (16.2%).
Croatian: Incidencija hipoglikemije bila je značajno manja u skupini liječenih vildagliptinom (1,7%) nego u skupini liječenih glimepiridom (16,2%).
English: Other side effects Some patients have experienced the following side effects while taking Zomarist:
Croatian: Neki su bolesnici imali sljedeće nuspojave kada su uzimali Zomarist:
English: Vildagliptin in combination with metformin and glimepiride significantly decreased HbA1c compared with placebo.
Croatian: Vildagliptin u kombinaciji s metforminom i glimepiridom značajno je snizio HbA1c u usporedbi s placebom.
English: Zomarist is indicated in the treatment of type 2 diabetes mellitus: - Zomarist is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
Croatian: Zomarist je indiciran u liječenju šećerne bolesti tipa 2: - Zomarist je indiciran u liječenju odraslih bolesnika u kojih se ne može postići zadovoljavajuća kontrola glikemije primjenom oralnog metformina u maksimalno podnošljivoj dozi ili u bolesnika koji se već liječe kombinacijom odvojenih tableta vildagliptina i metformina.
English: In the subgroups treated with insulin with or without concomitant metformin the placebo-adjusted mean reduction in HbA1c was -0.63% and -0.84%, respectively.
Croatian: U podskupinama liječenim inzulinom sa ili bez istodobne primjene metformina prosječno sniženje HbA1c, prilagođeno s obzirom na placebo, bilo je -0,63% odnosno -0,84%.
English: No increases in tumour incidence attributable to vildagliptin were observed.
Croatian: Nisu zapažena povećanja incidencije tumora koja bi se mogla pripisati vildagliptinu.
English: Bioequivalence has been demonstrated between Zomarist at three dose strengths (50 mg/500 mg, 50 mg/850 mg and 50 mg/1000 mg) versus free combination of vildagliptin and metformin hydrochloride tablets at the corresponding doses.
Croatian: Potvrđena je bioekvivalencija triju jačina doza Zomariste (50 mg/500 mg, 50 mg/850 mg i 50 mg/1000 mg) u usporedbi sa slobodnom kombinacijom tableta vildagliptina i metforminklorida u odgovarajućim dozama.
English: Zomarist combines two antihyperglycaemic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: vildagliptin, a member of the islet enhancer class, and metformin hydrochloride, a member of the biguanide class.
Croatian: Zomarist sadrži kombinaciju dviju antihiperglikemijskih tvari s komplementarnim mehanizmima djelovanja za poboljšanje kontrole glikemije u bolesnika sa šećernom bolešću tipa 2: vildagliptin, pripadnik skupine stimulatora Langerhansovih otočića gušterače i metforminklorid, pripadnik skupine bigvanida.
English: Rare cases of angioedema have been reported on vildagliptin at a similar rate to controls.
Croatian: U bolesnika na vildagliptinu zabilježeni su rijetki slučajevi angioedema sa sličnom stopom kao u kontrolnim skupinama.
English: Vildagliptin added to patients whose glycaemic control was not satisfactory despite treatment with metformin monotherapy resulted after 6-month treatment in additional statistically significant mean reductions in HbA1c compared to placebo (between group differences of -0.7% to -1.1% for vildagliptin 50 mg and 100 mg, respectively).
Croatian: Dodatak vildagliptina bolesnicima u kojih nije postignuta zadovoljavajuća kontrola glikemije usprkos monoterapiji metforminom rezultirao je nakon 6-mjesečnog liječenja dodatnom statistički značajnom srednjom vrijednosti smanjenja HbA1c u usporedbi s placebom (razlika između skupina od -0,7% do -1,1% za vildagliptin u dozi od 50 mg i 100 mg).
English: Patients receiving vildagliptin experienced no weight gain (+0.2 kg) while those receiving placebo experienced weight reduction (-0.7 kg).
Croatian: U bolesnika koji su primali vildagliptin nije došlo do povećanja tjelesne težine (+0,2 kg), dok je u onih bolesnika koji su primali placebo došlo do smanjenja tjelesne težine (-0,7 kg).
English: The recommended dose is one film-coated tablet of either 50 mg/850 mg or 50 mg/1000 mg taken twice a day
Croatian: Preporučena doza je jedna filmom obložena tableta od 50 mg/850 mg ili 50 mg/1000 mg koja se uzima dvaput na dan.
English: Body weight change with vildagliptin was +0.1 kg compared to a weight gain of +1.4 kg with gliclazide.
Croatian: Promjena tjelesne težine uz vildagliptin bila je +0,1 kg u usporedbi s dobitkom na težini od +1,4 kg uz gliklazid.
English: A test to determine your liver function will be performed before the start of Zomarist treatment, at three-month intervals for the first year and periodically thereafter.
Croatian: Testovi jetrene funkcije će se napraviti prije početka liječenja Zomaristom, potom tijekom prve godine u razmacima od tri mjeseca te poslije toga periodički.
English: The incidence of hypoglycaemia was common in both treatment groups (5.1% for the vildagliptin + metformin + glimepiride group versus 1.9% for the placebo + metformin + glimepiride group).
Croatian: Incidencija hipoglikemije bila je česta u obje skupine ispitanika (5,1% u skupini koja je primala vildagliptin + metformin + glimepirid u odnosu na 1,9% u skupini koja je primala placebo + metformin + glimepirid).
English: DPP-4 inhibition by vildagliptin is not affected by gender.
Croatian: Spol ne utječe na inhibiciju DPP-4 vildagliptinom.
English: Zomarist is used to treat adult patients with type 2 diabetes.
Croatian: Zomarist se primjenjuje za liječenje bolesnika sa šećernom bolešću tipa
English: • Frequency not known (cannot be estimated from the available data): itchy rash, inflammation of the pancreas, localised peeling of skin or blisters, muscle pain.
Croatian: • učestalost nije poznata (učestalost se ne može procijeniti iz dostupnih podataka): osip koji svrbi, upala gušterače, lokalizirano ljuštenje kože ili mjehurići, bol u mišiću.
English: - For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin
Croatian: - U bolesnika u kojih nije postignuta zadovoljavajuća kontrola dvojnom kombiniranom terapijom inzulinom i najvišom podnošljivom dozom metformina:
English: By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion.
Croatian: Povećavanjem endogenih razina ovih inkretinskih hormona vildagliptin povećava osjetljivost beta stanica na glukozu, što rezultira poboljšanjem sekrecije inzulina koja ovisi o glukozi.
English: In comparative controlled monotherapy studies, hypoglycaemia was uncommon, reported in 0.4% (7 of 1,855) of patients treated with vildagliptin 100 mg daily compared to 0.2% (2 of 1,082) of patients in the groups treated with an active comparator or placebo, with no serious or severe events reported.
Croatian: U usporednim kontroliranim ispitivanjima monoterapije hipoglikemija je bila manje česta, a zabilježena je u 0,4% (7 od 1855) bolesnika liječenih sa 100 mg vildagliptina na dan, u odnosu na 0,2% (2 od 1082) bolesnika u skupinama liječenim aktivnim lijekom usporedbe ili placebom, pri čemu nisu zabilježeni ozbiljni ili teški događaji.
English: 60 film-coated tablets.
Croatian: Filmom obložena tableta 60 filmom obloženih tableta.
English: There were no withdrawals due to adverse reactions reported in the vildagliptin + metformin + glimepiride treatment group versus 0.6% in the placebo + metformin + glimepiride treatment group.
Croatian: Nije bilo povlačenja iz ispitivanja uslijed prijavljenih nuspojava u skupini koja je primala terapiju vildagliptinom + metforminom + glimepiridom u odnosu na 0,6% u skupini koja je primala terapiju placebom + metforminom + glimepiridom.
English: • Common (may affect up to 1 in 10 people): dizziness, headache, trembling that cannot be controlled, metallic taste, low blood glucose.
Croatian: • često (mogu se javiti u 1 na 10 osoba): omaglica, glavobolja, nekontrolirano drhtanje, metalni okus, niska razina glukoze u krvi.
English: After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.
Croatian: Neapsorbirana frakcija otkrivena u stolici nakon oralne doze je bila 20-30%.
English: If necessary, the dosage of Zomarist may need to be adjusted during concomitant therapy and on its discontinuation.
Croatian: Ako je potrebno, dozu Zomariste treba prilagoditi za vrijeme istodobne primjene te nakon njenog završetka.
English: There may be an increased risk of angioedema in patients concomitantly taking ACE inhibitors.
Croatian: Može postojati povećani rizik od angioedema u bolesnika koji istodobno uzimaju ACE inhibitore (vidjeti dio 4.8).
English: Intra-cardiac impulse conduction delays were observed in dogs with a no-effect dose of 15 mg/kg (7fold human exposure based on Cmax).
Croatian: Zastoji intrakardijalnog provođenja impulsa zapaženi su u pasa, pri čemu doza koja ne izaziva učinak iznosi 15 mg/kg (7-struka izloženost u ljudi na temelju Cmax).
English: The elimination half-life after oral administration is approximately 3 hours.
Croatian: Poluvrijeme eliminacije nakon peroralne primjene iznosi oko 3 sata.
English: The decrease in HbA1c observed in patients with a baseline ≥10.0% was greater.
Croatian: Uočeno je veće sniženje HbA1c u bolesnika s početnom vrijednosti ≥10,0%.
English: In particular, if you are following a diabetic weight control diet, continue with this while you are taking Zomarist.
Croatian: Ako se trebate pridržavati dijabetičke dijete za kontrolu tjelesne težine, onda svakako nastavite s njom i za vrijeme uzimanja Zomariste.
English: In these cases, the patients were generally asymptomatic without clinical sequelae and liver function tests (LFTs) returned to normal after discontinuation of treatment.
Croatian: U tim slučajevima bolesnici su općenito bili bez simptoma i kliničkih posljedica, a testovi jetrene funkcije su se vratili na normalu nakon prekida liječenja.
English: A 24-week randomised, double-blind, placebo-controlled trial was conducted in 449 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with a stable dose of basal or premixed insulin (mean daily dose 41 units), with concomitant use of metformin (N=276) or without concomitant metformin (N=173).
Croatian: 24-tjedno, randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno je u 449 bolesnika kako bi se ocijenila djelotvornost i sigurnost primjene vildagliptina (50 mg dvaput na dan) u kombinaciji sa stabilnom dozom bazalnog ili predmiješanog inzulina (srednja dnevna doza od 41 jedinice) uz istodobnu primjenu metformina (N=276) ili bez istodobne primjene metformina (N=173).
English: Metabolism and nutrition disorders Very Rare
Croatian: Poremećaji metabolizma i prehrane Vrlo rijetko
English: - Zomarist is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.
Croatian: - Zomarist je indiciran u kombinaciji sa sulfonilurejom (tj. trojna kombinirana terapija) kao dodatak dijeti i tjelovježbi u odraslih bolesnika u kojih je kontrola nedostatna s metforminom i sulfonilurejom.
English: There have been no studies of metformin added to vildagliptin.
Croatian: Ne postoje ispitivanja u kojima je metformin dodan vildagliptinu.
English: In another 24-week study in patients with more advanced type 2 diabetes not adequately controlled on insulin (short and longer acting, average insulin dose 80 IU/day), the mean reduction in HbA1c when vildagliptin (50 mg twice daily) was added to insulin was statistically significantly greater than with placebo plus insulin (0.5% vs. 0.2%).
Croatian: U drugom 24-tjednom ispitivanju s bolesnicima s uznapredovalom šećernom bolešću tipa 2 u kojih terapijom inzulinom nije postignuta odgovarajuća kontrola (prosječna doza inzulina kratkog ili dugog djelovanja 80 IU/dan), prosječno sniženje HbA1c kad je vildagliptin (50 mg dvaput na dan) bio pridodan inzulinu bilo je statistički značajno veće nego kad je inzulinu bio pridodan placebo (0,5% u odnosu na 0,2%).
English: The overall incidence of withdrawals from controlled monotherapy trials due to adverse reactions was no greater for patients treated with vildagliptin at doses of 100 mg daily (0.3%) than for placebo (0.6%) or comparators (0.5%).
Croatian: Ukupna incidencija povlačenja iz kontroliranih ispitivanja monoterapije zbog nuspojava nije bila veća u bolesnika koji su liječeni vildagliptinom u dozama od 100 mg na dan (0,3%), u odnosu na bolesnike koji su primali placebo (0,6%) ili lijekove usporedbe (0,5%).
English: Intravascular administration of iodinated contrast agents lead to contrast-induced nephropathy, resulting in metformin accumulation and increased risk of lactic acidosis.
Croatian: Intravaskularna primjena jodiranih kontrastnih sredstava može dovesti do nefropatije izazvane kontrastom, što dovodi do nakupljanja metformina i povećanja rizika od laktacidoze.